Therapeutic efficacy of radiofrequency ablation combined with chemotherapy for advanced nonsmall cell lung cancer
CHEN Di-yao;YE Jun;XIONG Xiang-lian;WANG Jian-peng;SHI De-gang;PENG Guo-wen;Department of Intervention,The First People's Hospital of Foshan;Department of Thoracic Surgery,The First People's Hospital of Foshan;
Objective To investigate the therapeutic efficacy of radiofrequency ablation combined with chemotherapy for advanced non-small cell lung cancer( NSCLC). Methods A total of 80 patients with advanced NSCLC treated at The First People's Hospital of Foshan from August 2014 to February 2017 were selected. They were randomly divided into an observation group and a control group by the random number table method,with 40 patients in each group. Patients in the observation group were treated with radiofrequency ablation combined with gemcitabine and cisplatin chemotherapy and patients in the control group were treated with gemcitabine and cisplatin chemotherapy. The short-term efficacy and incidence of adverse reactions were compared between the two groups. The K-M time survival curve was drawn and the median survival time was compared between the two groups by Log-Rank test. Results Hemoptysis occurred in5 patients,fever in 7 patients,chest pain in 9 patients,gastrointestinal reaction in 50 patients and alopecia in34 patients during the treatment. There was no significant difference in the incidence of adverse reactions between the two groups( P 0. 05). At 1 month after the treatment,the CT values significantly decreased in the two groups with the decreation more significant in the observation group than in the control group( all P 0. 05). At 1 month after the treatment,the disease control rate( DCR) was 90. 0% for the observation group which was significantly higher than72. 5% of the control group( P 0. 05). Compared with the control group,the DCR were 96. 0%,81. 2% and 75. 0%,respectively in patients with tumor size of 3 to 4. 9 cm,5 to6. 9 cm and 7 to 9 cm( all P 0. 05). At the last follow-up,26 patients died and 14 patients were still alive in the observation group compared with 33 patients and 7 patients in the control group and the survival rate was 35. 0% and 17. 5% respectively for the observation group and the control group( P 0. 05). The median survival time was 440 dand 254 d for the observation group and the control group respectively and LogRank test showed that the difference was significant( P 0. 05). Conclusion Radiofrequency ablation combined with chemotherapy is effective in the treatment of advanced non-small cell lung cancer. It can significantly improve the disease control rate,prolong the survival time,without increasing the adverse reactions.
【CateGory Index】： R734.2